Pfizer Advances Tilrekimig Into Phase 3 Atopic Dermatitis And Asthma Trials After Phase 2 Study Showed Statistically Significant EASI-75 Gains At Week 16 And No Dose-Dependent Safety Signals

Benzinga Newsdesk www.benzinga.com Positive 92.1%

Neg 0% Neu 0% Pos 92.1%

Comments

No comments yet. Be the first!